Abvc Biopharma (ABVC) Gross Margin (2016 - 2024)
Abvc Biopharma's (ABVC) quarterly Gross Margin came in at 100.0% in Q4 2024, up 642984.0% on a YoY basis from N/an in Q1 2024, and little changed quarter-over-quarter from 99.92% in Q3 2024.
Powered by 
Analysis
Abvc Biopharma (ABVC) Gross Margin (2016 - 2024) Analysis & Trends
Abvc Biopharma (ABVC) has reported Gross Margin for 9 consecutive years, with 100.0% the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Gross Margin rose 642984.0% year-over-year to 100.0%; the trailing twelve-month figure through Dec 2024 stood at 99.85% (up 19800.0% YoY), and the FY2025 full-year result was 100.0%, up 15.0% from the prior year.
- Gross Margin was little changed at 100.0% in Q4 2024 per ABVC's latest filing, from 99.92% in the prior quarter.
- Across five years, Gross Margin topped out at 107.41% in Q4 2021 and bottomed at 6329.84% in Q4 2023.
- Historically, Gross Margin has averaged 298.73% across 5 years, with a median of 95.96% in 2020.
- The sharpest annual moves came in 2023 and 2024: Gross Margin slumped 638478 bps in 2023, then jumped 642984 bps in 2024.
- Over 5 years, Gross Margin stood at 96.94% in 2020, then rose by 11 bps to 107.41% in 2021, then plunged by 49 bps to 54.94% in 2022, then slumped by 11622 bps to 6329.84% in 2023, then surged by 102 bps to 100.0% in 2024.
- According to Business Quant data, Gross Margin over the past three periods registered 100.0%, 99.92%, and 99.84% for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 80.31% |
| 10 | Abvc Biopharma | 25.56 Mn | 25.56 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 99.92% |
| Jun 30, 2024 | 99.84% |
| Mar 31, 2024 | 77.01% |
| Dec 31, 2023 | -6,329.84% |
| Sep 30, 2023 | -86.44% |
| Jun 30, 2023 | -1,094.65% |
| Mar 31, 2023 | 53.04% |
| Dec 31, 2022 | 54.94% |
| Sep 30, 2022 | 74.59% |
| Jun 30, 2022 | 97.33% |
| Mar 31, 2022 | 92.61% |
| Dec 31, 2021 | 107.41% |
| Sep 30, 2021 | 99.60% |
| Jun 30, 2021 | 97.95% |
| Mar 31, 2021 | 99.53% |
| Dec 31, 2020 | 96.94% |
| Sep 30, 2020 | 92.54% |
| Jun 30, 2020 | 98.13% |
| Mar 31, 2020 | 94.97% |